SELB Selecta Biosciences Inc.

2.3
-0.01  -0%
Previous Close 2.31
Open 2.31
Price To Book -19.17
Market Cap 97685085
Shares 42,471,776
Volume 250,435
Short Ratio
Av. Daily Volume 590,355

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Head to head trial vs Krystexxa initiation announced March 29, 2019 with interim data due 4Q 2019 and full data 1Q 2020.
SEL-212 (COMPARE)
Tophaceous gout
Grade 5 SAE reported October 17, 2018.
SEL-403
Mesothelioma

Latest News

  1. Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
  2. Will Selecta Biosciences Continue to Surge Higher?
  3. Selecta Biosciences to Present at the Needham & Company 18th Annual Healthcare Conference April 9, 2019
  4. Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
  5. Selecta Biosciences Announces New Employment Inducement Grant
  6. Edited Transcript of SELB earnings conference call or presentation 15-Mar-19 12:30pm GMT
  7. Selecta Biosciences Announces Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
  8. Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update
  9. Selecta Biosciences to Present at the Cowen Annual Health Care Conference March 13, 2019
  10. IBD Stock Of The Day: Top-Rated Pharma Stock Approaches Breakout
  11. Selecta Biosciences Announces Pricing of Public Offering of Common Stock
  12. The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
  13. Selecta Biosciences Announces Proposed Public Offering of Common Stock
  14. Selecta Biosciences Enters Oversold Territory
  15. Watertown biotech Selecta drops cancer drug, cuts staff
  16. Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.
  17. What Kind Of Shareholder Appears On The Selecta Biosciences Inc’s (NASDAQ:SELB) Shareholder Register?
  18. Selecta Biosciences Announces New Employment Inducement Grants
  19. Edited Transcript of SELB earnings conference call or presentation 8-Nov-18 1:30pm GMT
  20. Report: Developing Opportunities within Command Center, Neurotrope, Selecta Biosciences, InVivo Therapeutics, SeaSpine, and Senestech — Future Expectations, Projections Moving into 2018